Dr Han speaks with ecancertv at SABCS 2016 about the outcomes from a trial of added velaparib to chemotherapy for BRCA1/2 mutant metastatic breast cancers.

Compared to carboplatin and paclitaxel, she describes the addition of velaparib as extending progression free survival, though not to a statistically significant extent, with no additional toxicity.

These results were first presented at a press conference session, with coverage available here.